China-based Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, announced on Wednesday positive preliminary results from its Phase IIa clinical trial of ISM001-055.
ISM001-055 is a first-in-class small molecule aimed at TNIK (Traf2- and Nck-interacting kinase) and was designed using generative AI to treat idiopathic pulmonary fibrosis (IPF). The primary and the secondary efficacy endpoints of the study have been met, demonstrating dose-dependent response in forced vital capacity (FVC), a critical measure of lung function in IPF patients.
The company's proprietary AI platform facilitated ISM001-055's target identification and molecular design. The Phase IIa study was a randomised, double-blind, placebo-controlled trial that enrolled 71 patients with IPF across 21 sites in China. Patients were randomised to receive either placebo, 30mg once daily (QD), 30mg twice daily (BID) or 60mg QD for a period of 12 weeks.
Complete topline data will be released at an upcoming medical conference and clinical trial results will be submitted for publication in a peer-reviewed journal.
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
IGC Pharma reports new data supporting IGC-AD1 to treat Alzheimer's
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
ValiRx's subsidiary Inaphaea signs agreement with Xenopat for Patient Derived Cells
IVIEW Therapeutics completes patient recruitment for dry eye disease clinical trial
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Xylyx Bio receives SBIR grant from NIDDK
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
Sareum Holdings secures patent allowance for SDC-1801 in China
Infex Therapeutics begins Phase IIa trial for RESP-X in NCFB patients